Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Calabrese A, Basile V, Puglisi S, Perotti P, Pia A, Saba L, Berchialla P, Porpiglia F, Veltri A, Volante M, Reimondo G, Berruti A, Terzolo M.
Calabrese A, et al. Among authors: saba l.
Eur J Endocrinol. 2019 Jun 1;180(6):387-396. doi: 10.1530/EJE-18-0923.
Eur J Endocrinol. 2019.
PMID: 30991359
Free article.